Home hero

Investing in Exponential Transformation

Founded in 2003 by Rebecka Belldegrun, M.D. and Arie Belldegrun, M.D., Bellco Capital is a direct investment firm that focuses on deploying capital to create and support companies with bold ambitions of exponential transformation in life science, real estate, consumer products, media, and other sectors.

At Bellco Capital, we believe that each and every investment is the start of a relationship that should benefit all involved. Our standard for these relationships is defined by our core beliefs – absolute integrity, passionate innovation, unfailing loyalty and the relentless pursuit of excellence.

Leadership

Arie Belldegrun

Arie Belldegrun, M.D.

Bell Co Capital11 18 N Gingold EDIT 206

Rebecka Belldegrun, M.D.

Bell Co Capital11 18 N Gingold EDIT 057

Josh Bradley

Read Full Profiles

Portfolio

We have a longstanding track record of founding and investing in life sciences companies that shift paradigms.

Our most notable impact has been leading the cell therapy field with the founding of Kite Pharma, acquired by Gilead Sciences in 2017 for $11.9 billion, and Allogene Therapeutics, the second-largest biotechnology IPO of 2018.

Btprop Full Blue
Urogen Blue
Kronos Blue
Kite Blue
First Media Blue
Hubble Blue
Celldesignlabs Blue
Cb logo
Byheart logo 2
Neogene Blue
See Our Portfolio
Kite Pharma Team Nasdaq
Kite Pharma celebrating a successful IPO with gross proceeds of $146.6 million in June 2014.
Arie EY
Arie Belldegrun, honored with the prestigious EY Master Entrepreneur Award during the Entrepreneur of the Year 2018 Awards Gala on Thursday, June 14, 2018 in Los Angeles.
MRT Drs Belldegrun ZL 180
Supervisor Mark Ridley Thomas extending LA County’s congratulations to Drs. Belldegrun at the groundbreaking ceremony of Kite Pharma’s El Segundo manufacturing facility on August 6, 2015.
Arie Rebecka ALLO Nasdaq
Rebecka and Arie Belldegrun ring the Nasdaq opening bell on October 12, 2018, to celebrate the public launch of Allogene Therapeutics, the second largest biotechnology IPO of 2018.
RB C Suite Panel
Rebecka Belldegrun with fellow C-Suite Panelists, Michelle Kydd Lee, Chief Innovation Officer of Creative Artists Agency, Marilyn Spiegel, President of Wynn Las Vegas, and Nadine Watt, President of Watt Companies. Hosted by the Century City Women’s Business Council on April 30 th in Century City.
Kite Pharma Gillead Deal 010
In October 2017 Gilead Sciences acquired Kite Pharma for $11.9 billion.

Our Partners

Deep and integrated relationships provide greater reach and visibility to passionate leaders and innovative technologies across life sciences. Our partners include:

Two River

Two river

Two River is a life sciences incubator that invests in businesses that change people’s lives. Two River works with experienced teams to build outstanding companies that improve health outcomes and quality of life. It invests in companies with strong intellectual property and proven leadership teams who have demonstrated prior success developing innovative technologies in the life sciences sector. Two River’s experience building companies spans a range of industry sectors including oncology, cardiovascular disease, ophthalmology, neurological disorders and animal health.

tworiver.com

Vida Ventures

Vida

Vida Ventures is a next-generation life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together they form an independent, bold investment group bound together by a simple word – life. Its mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently has approximately $1 billion in assets under management.

vidaventures.com

Breakthrough Properties

Breakthrough

Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. It combines Tishman-Speyer’s decades of global real estate development experience with Bellco Capital’s industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients. Breakthrough seeks to create and expand highly functional, well-located centers of excellence in the world’s key life science research centers.

btprop.com

Pontifax AgTech

Leaf7

Pontifax AgTech is a growth capital firm dedicated to food and agriculture technology. The firm manages over $450M in AUM from leading institutions, endowments and foundation. Pontifax sits on the intersection of life sciences, data/IT and the food and agriculture sector. The firm invests in businesses that improve the productivity, efficiency and sustainability of one of the most critical industries in the world.

pontifaxagtech.com